Some of the most devastating tumors develop due to the loss of function in tumor suppressor genes. These tumors are often incredibly difficult to treat, and in most cases, no targeted treatments exist. However, significant advances in tumor genome sequencing have revealed the “Achilles’ heels” of these tumors, including molecular motors that drive structural rearrangements within the tumor genome. Eisbach Bio has developed a method to directly combat these tumors using our proprietary epigenetic key technologies. Leveraging our unique screening and cell platform technology, we are developing first-class drugs that correct these disruptive changes in tumors. We can achieve this in a highly specific manner that spares healthy cells. In 2024, Eisbach will initiate the clinical trial of EIS-12656, our leading oncology program, at the MD Anderson Cancer Center at the University of Texas in Houston to evaluate the safety, tolerability, and efficacy of the small molecule.

We are a bold, curious, and strong team dedicated to transforming patients’ lives and be stewards of our community. Eisbach aims to create groundbreaking therapeutics for treating incurable cancers based on the principle of synthetic lethality. We are committed to making cancers with tumor suppressor deficiencies treatable and will harness our latest scientific discoveries to pioneer new drugs and improve the lives of many patients for whom there is currently no cure.